Pluri (PLUR) Non Operating Interest Expenses (2010 - 2025)
Pluri's (PLUR) quarterly Non Operating Interest Expenses came in at $231000.0 in Q4 2025, up 9.48% year-over-year from $211000.0 in Q4 2024, and up 0.87% quarter-over-quarter from $229000.0 in Q3 2025.
Analysis
Pluri (PLUR) Non Operating Interest Expenses (2010 - 2025) Analysis & Trends
Pluri (PLUR) has reported Non Operating Interest Expenses for 8 consecutive years, with $231000.0 the latest figure, recorded in Q4 2025.
- On a quarterly basis, Non Operating Interest Expenses rose 9.48% year-over-year to $231000.0 in Q4 2025; TTM through Dec 2025 was $905000.0, a 4.75% increase from a year earlier, with the FY2025 full-year figure at $873000.0, up 0.81% from the prior year.
- Non Operating Interest Expenses was $231000.0 for Q4 2025 at Pluri, up from $229000.0 in the prior quarter.
- Over five years, Non Operating Interest Expenses peaked at $233000.0 in Q2 2025 and troughed at $194000.0 in Q3 2022.
- A 4-year average of $217285.7 and a median of $217000.0 in 2023 frame the typical range for Non Operating Interest Expenses.
- Across the five-year window, Non Operating Interest Expenses grew 10.31% in 2023 and fell 2.75% in 2025, its largest moves.
- Over 4 years, Non Operating Interest Expenses stood at $212000.0 in 2022, then gained by 1.89% to $216000.0 in 2023, then declined by 2.31% to $211000.0 in 2024, then grew by 9.48% to $231000.0 in 2025.
- The last three Non Operating Interest Expenses figures came in at $231000.0 (Q4 2025), $229000.0 (Q3 2025), and $233000.0 (Q2 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Interest Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Krystal Biotech | 10.27 Bn | 9.43 Bn | 112.79 Mn | - |
| 2 | CRISPR Therapeutics AG | 5.17 Bn | 5.17 Bn | - | - |
| 3 | Iovance Biotherapeutics | 3.79 Bn | 3.49 Bn | 55.72 Mn | 4.00 Bn |
| 4 | Legend Biotech | 3.68 Bn | 2.71 Bn | 251.50 Mn | -5.80 Mn |
| 5 | uniQure | 3.05 Bn | 3.05 Bn | 5.49 Mn | 14.37 Mn |
| 6 | Beam Therapeutics | 2.65 Bn | 2.65 Bn | - | - |
| 7 | Precigen | 2.44 Bn | 2.44 Bn | 52.17 Mn | 2.95 Mn |
| 8 | Sarepta Therapeutics | 2.33 Bn | 1.53 Bn | 251.87 Mn | - |
| 9 | Vericel | 1.99 Bn | 1.83 Bn | 56.40 Mn | 160,000.00 |
| 10 | Pluri | 11.95 Mn | -536,034.04 | 86,000.00 | 231,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 231,000.00 |
| Sep 30, 2025 | 229,000.00 |
| Jun 30, 2025 | 233,000.00 |
| Mar 31, 2025 | 212,000.00 |
| Dec 31, 2024 | 211,000.00 |
| Sep 30, 2024 | 217,000.00 |
| Jun 30, 2024 | 218,000.00 |
| Mar 31, 2024 | 218,000.00 |
| Dec 31, 2023 | 216,000.00 |
| Sep 30, 2023 | 214,000.00 |
| Jun 30, 2023 | 220,000.00 |
| Mar 31, 2023 | 217,000.00 |
| Dec 31, 2022 | 212,000.00 |
| Sep 30, 2022 | 194,000.00 |
| Sep 30, 2013 | 105,000.00 |
| Jun 30, 2013 | 226,000.00 |
| Mar 31, 2013 | 253,000.00 |
| Dec 31, 2012 | 394.00 |
| Sep 30, 2012 | 195,000.00 |
| Jun 30, 2012 | -164,000.00 |